JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB311139

Alexa Fluor® 647 Anti-Somatostatin 28 antibody [EPR3359(2)]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Somatostatin antibody - conjugated to Alexa Fluor® 647. Suitable for Target Binding Affinity, Antibody Labelling, IHC-P and reacts with Human, Mouse, Rat samples.

View Alternative Names

Somatostatin, Growth hormone release-inhibiting factor, SST

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Somatostatin 28 antibody [EPR3359(2)]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-Somastatin 28 antibody [EPR3359(2)]

  • 603 Alexa Fluor® 568

    Alexa Fluor® 568 Anti-Somatostatin 28 antibody [EPR3359(2)]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Somatostatin 28 antibody [EPR3359(2)]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-Somatostatin 28 antibody [EPR3359(2)]

  • Carrier free

    Anti-Somatostatin 28 antibody [EPR3359(2)] - BSA and Azide free

  • Unconjugated

    Anti-Somatostatin 28 antibody [EPR3359(2)]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR3359(2)

Isotype

IgG

Conjugation

Alexa Fluor® 647

Excitation/Emission

Ex: 650nm, Em: 665nm

Carrier free

No

Reacts with

Human, Mouse, Rat

Applications

Antibody Labelling, IHC-P, Target Binding Affinity

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Complementary Products

Proteins & Peptides

AB159587

Recombinant Human Somatostatin protein (GST tag N-Terminus)

SDS-PAGE - Recombinant Human Somatostatin protein (GST tag N-Terminus) (AB159587)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "TargetBindingAffinity" : {"fullname" : "Target Binding Affinity", "shortname":"Target Binding Affinity"}, "AntibodyLabelling" : {"fullname" : "Antibody Labelling", "shortname":"Antibody Labelling"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "TargetBindingAffinity-species-checked": "guaranteed", "TargetBindingAffinity-species-dilution-info": "", "TargetBindingAffinity-species-notes": "", "AntibodyLabelling-species-checked": "guaranteed", "AntibodyLabelling-species-dilution-info": "", "AntibodyLabelling-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Mouse": { "TargetBindingAffinity-species-checked": "guaranteed", "TargetBindingAffinity-species-dilution-info": "", "TargetBindingAffinity-species-notes": "", "AntibodyLabelling-species-checked": "guaranteed", "AntibodyLabelling-species-dilution-info": "", "AntibodyLabelling-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Rat": { "TargetBindingAffinity-species-checked": "guaranteed", "TargetBindingAffinity-species-dilution-info": "", "TargetBindingAffinity-species-notes": "", "AntibodyLabelling-species-checked": "guaranteed", "AntibodyLabelling-species-dilution-info": "", "AntibodyLabelling-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" } } }
style
left-column

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Somatostatin 28 also known as SST-28 is a biologically active peptide that functions as a hormone. It is an alternate form of somatostatin the other being somatostatin-14. Somatostatin 28 is characterized by its longer peptide chain with a molecular mass of approximately 3.2 kDa. This peptide is expressed mainly in the central nervous system particularly in the hypothalamus and in the gastrointestinal tract. Its synthesis involves specific posttranslational processing steps and it acts in various cellular locations performing regulatory roles in endocrine and exocrine systems.
Biological function summary

Somatostatin 28 plays an important role in inhibiting the release of certain hormones and neurotransmitters. It exerts its effects by binding to specific somatostatin receptors which are part of a family of G-protein-coupled receptors. These receptors when activated by somatostatin 28 can inhibit adenylyl cyclase activity reducing cyclic AMP levels and therefore suppressing hormone secretion. While somatostatin 28 does not form part of a large multi-protein complex it acts collaboratively with related peptides and receptors to modulate neuronal and digestive functions.

Pathways

Somatostatin 28 participates centrally in the regulation of the endocrine signaling pathways notably influencing the growth hormone inhibitory pathway. This pathway involves interconnected proteins such as growth hormone-releasing hormone (GHRH) which somatostatin 28 suppresses. Additionally the peptide plays a role in modulating the insulin signaling pathway where it inhibits the secretion of insulin. These pathways highlight somatostatin 28's regulatory influence on metabolism and cellular growth by interacting with other proteins like insulin and GHRH.

Somatostatin 28 is implicated in conditions such as acromegaly and certain types of diabetes. In acromegaly excessive growth hormone production often due to pituitary adenomas is counteracted by somatostatin 28's inhibitory effects. The peptide's interaction with the receptor-bound growth hormone contributes to potential therapeutic approaches to managing this disorder. In diabetes specifically type 2 somatostatin 28's role in inhibiting insulin release provides insight into its involvement in glucose metabolism dysregulation. Understanding these connections highlights the importance of somatostatin 28 and related proteins like insulin in the pathophysiology of metabolic diseases.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Somatostatin-14. Inhibits the secretion of pituitary hormones, including that of growth hormone/somatotropin (GH1), PRL, ACTH, luteinizing hormone (LH) and TSH. Also impairs ghrelin- and GnRH-stimulated secretion of GH1 and LH; the inhibition of ghrelin-stimulated secretion of GH1 can be further increased by neuronostatin.. Neuronostatin. May enhance low-glucose-induced glucagon release by pancreatic alpha cells (By similarity). This effect may be mediated by binding to GPR107 and PKA activation (By similarity). May regulate cardiac contractile function (By similarity). May compromise cardiomyocyte viability (By similarity). In the central nervous system, may impair memory retention and may affect hippocampal excitability (By similarity). May also have anxiolytic and anorexigenic effects (By similarity). May play a role in arterial pressure regulation (By similarity). May inhibit basal, but not ghrelin- or GnRH-stimulated secretion of GH1 or LH, but does not affect the release of other pituitary hormones, including PRL, ACTH, FSH or TSH. Potentiates inhibitory action of somatostatin on ghrelin-stimulated secretion of GH1, but not that on GnRH-stimulated secretion of LH (PubMed : 29615476).
See full target information SST
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com